Compounds > 2h-1,4-benzoxazine, 3,4-dihydro-2,2-dimethyl-6-nitro-4-(2-pyridinyl)-, n-oxide
Page last updated: 2024-09-03

2h-1,4-benzoxazine, 3,4-dihydro-2,2-dimethyl-6-nitro-4-(2-pyridinyl)-, n-oxide and Myocardial Infarction

2h-1,4-benzoxazine, 3,4-dihydro-2,2-dimethyl-6-nitro-4-(2-pyridinyl)-, n-oxide has been researched along with Myocardial Infarction in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Taguchi, T; Takenaka, T; Takeo, S; Uchida, W1

Other Studies

1 other study(ies) available for 2h-1,4-benzoxazine, 3,4-dihydro-2,2-dimethyl-6-nitro-4-(2-pyridinyl)-, n-oxide and Myocardial Infarction

ArticleYear
Reduction by ATP-sensitive potassium channel opener, YM934, of experimental myocardial infarct size in anesthetized dogs.
    Pharmacology, 1999, Volume: 59, Issue:2

    Topics: Animals; Benzoxazines; Calcium Channel Blockers; Coronary Vessels; Cyclic N-Oxides; Dogs; Drug Evaluation, Preclinical; Female; Hemodynamics; Hydralazine; Male; Myocardial Infarction; Nifedipine; Oxazines; Potassium Channels; Vasodilator Agents

1999